Bruce & Co’s Beta Bionics BBNX Stock Holding History

Bruce & Co’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Buy	665,700 +115,000	+21%	+$1.37M	2.82%	13
2026 Q1	$5.52M	Buy	+550,700	New	+$8.15M	1.58%	22

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bruce & Co's BBNX Position: Q2 2026 in Review

Bruce & Co increased its Beta Bionics (BBNX) stake by 21% in Q2 2026, buying an estimated $1.37M and bringing the position to 665,700 shares worth $10.4M. The position accounts for 2.82% of the portfolio, ranked #13.

Bruce & Co first reported a position in BBNX in Q1 2026 and has held it in 2 quarters since. 134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

Bruce & Co held 665,700 shares of Beta Bionics worth $10.4M as of Q2 2026.
Bruce & Co bought 115,000 Beta Bionics shares in Q2 2026, an estimated $1.37M.
Beta Bionics made up 2.82% of Bruce & Co's portfolio in Q2 2026, its #13 holding.
Bruce & Co first reported a position in Beta Bionics in Q1 2026 and has held it in 2 quarters since.
134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Bruce & Co's 13F filing for Q2 2026, filed 14 Aug 2026.